PharmaVoice Logo

Healthcare Leaders Hub

Immutep Reports Disease-Free Survival Data from the P-II (EFTISARC-NEO) Trial of Eftilagimod Alfa for Soft Tissue Sarcoma at CTOS 2026

PharmaShots

Immutep Reports Disease-Free Survival Data from the P-II (EFTISARC-NEO) Trial of Eftilagimod Alfa for Soft Tissue Sarcoma at CTOS 2026

Shots: Immutep has reported new data from the investigator-initiated P-II (EFTISARC-NEO) study of eftilagimod alfa (efti) + Keytruda (pembrolizumab) & radiotherapy as neoadjuvant treatment in patients with high-risk, resectable soft tissue sarcoma at CTOS 2026 (Poster P 448); of 40 enrolled pts, 38 underwent surgery & were evaluated for survival The study showed a 12mos… The post Immutep Reports Disease-Free Survival Data from the P-II (EFTISARC-NEO) Trial of Eftilagimod Alfa for Soft Tissue Sarcoma at CTOS 2026 appeared first on PharmaShots.

Read Full Article
Zealand Pharma Initiates the P-II (ZYNERGY) Trial of Petrelintide Co-Administered with Enicepatide for Obesity or Overweight

PharmaShots

Zealand Pharma Initiates the P-II (ZYNERGY) Trial of Petrelintide Co-Administered with Enicepatide for Obesity or Overweight

Shots: Ref: Globe Newswire  |   Image: Zealand Pharma  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Zealand Pharma Initiates the P-II (ZYNERGY) Trial of Petrelintide Co-Administered with Enicepatide for Obesity or Overweight appeared first on PharmaShots.

Read Full Article
Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases

Express Pharma

Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases

Starna to receive upfront payment of $330 million, eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products The post Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases appeared first on Express Pharma.

Read Full Article
Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026

PharmaShots

Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026

Shots: Acadia has presented additional data from the P-II (RADIANT) trial of once-daily remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) at CTAD 2026, building on the previously reported topline results At wk.6, the 60 mg dose was favored over placebo on CGI-I-ADP at wks. 2, 4 and 6 (nominal p=0.0232, 0.0082… The post Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026 appeared first on PharmaShots.

Read Full Article
Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors

PharmaShots

Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors

Shots: Ensem Therapeutics has dosed the first patients in its first-in-human P-I/II trial of ETX-929, an oral pan-KRAS inhibitor, in advanced solid tumors with KRAS alterations, including colorectal, pancreatic, NSCLC and gynecologic cancers The open-label, multicenter dose-escalation and expansion study will assess the safety, tolerability, PK, PD and preliminary antitumor activity of ETX-929 as monotherapy… The post Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors appeared first on PharmaShots.

Read Full Article

Sponsored content

Featured promotional

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer

News

Latest stories

PharmaShots

Nov 19, 2026, 6:09 AM

Immutep Reports Disease-Free Survival Data from the P-II (EFTISARC-NEO) Trial of Eftilagimod Alfa for Soft Tissue Sarcoma at CTOS 2026

Shots: Immutep has reported new data from the investigator-initiated P-II (EFTISARC-NEO) study of eftilagimod alfa (efti) + Keytruda (pembrolizumab) & radiotherapy as neoadjuvant treatment in patients with high-risk, resectable soft tissue sarcoma at CTOS 2026 (Poster P 448); of 40 enrolled pts, 38 underwent surgery & were evaluated for survival The study showed a 12mos… The post Immutep Reports Disease-Free Survival Data from the P-II (EFTISARC-NEO) Trial of Eftilagimod Alfa for Soft Tissue Sarcoma at CTOS 2026 appeared first on PharmaShots.

PharmaShots

Nov 19, 2026, 6:06 AM

Zealand Pharma Initiates the P-II (ZYNERGY) Trial of Petrelintide Co-Administered with Enicepatide for Obesity or Overweight

Shots: Ref: Globe Newswire  |   Image: Zealand Pharma  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Zealand Pharma Initiates the P-II (ZYNERGY) Trial of Petrelintide Co-Administered with Enicepatide for Obesity or Overweight appeared first on PharmaShots.

Express Pharma

Nov 19, 2026, 4:35 AM

Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases

Starna to receive upfront payment of $330 million, eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products The post Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases appeared first on Express Pharma.

ET Pharma

Nov 19, 2026, 2:18 AM

Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal

The agreement gives Pfizer rights to develop and commercialize three early-stage autoimmune disease programs outside Greater China, with initial clinical trial supplies to be manufactured at its US facilities.

ET Pharma

Nov 19, 2026, 2:14 AM

Pharma multinationals seek time-bound review of IND applications; may settle for six-year data exclusivity

MNC body, OPPI, has submitted formal representations to the CDSCO, seeking a US FDA-style, time-bound review of new drug applications. The lobby may revise its key demand of granting regulatory data production from 10 years to six years, in line with the protection period recently introduced by China.

ET Pharma

Nov 19, 2026, 12:24 AM

Shaw calls for tax incentives, easier biotech listings

Mazumdar-Shaw said early-stage, research-driven and pre-revenue biotech companies should be allowed to access public markets. Without such avenues, they risk being stranded without the capital needed to scale their research and businesses.

News

Latest industry coverage

Google News

Nov 19, 2026, 5:40 AM

Sentiment Among Professionals and Executives in the Chemical and Pharmaceutical Industries Remains Stable - chemeurope.com

Sentiment Among Professionals and Executives in the Chemical and Pharmaceutical Industries Remains Stable  chemeurope.com

Google News

Nov 19, 2026, 4:16 AM

Pharma leaders rate ability to act on diagnostic insights just 5.2/10, Diaceutics survey finds - News-Medical

Pharma leaders rate ability to act on diagnostic insights just 5.2/10, Diaceutics survey finds  News-Medical

Google News

Nov 19, 2026, 4:05 AM

Piramal Pharma acquisition: Company to buy remaining 26% stake in Yapan Bio - BusinessLine

Piramal Pharma acquisition: Company to buy remaining 26% stake in Yapan Bio  BusinessLine

Google News

Nov 19, 2026, 3:30 AM

Fangzhou and Baiyunshan Pharmaceutical Launch AI-Powered Chronic Disease Management Initiative - Morningstar

Fangzhou and Baiyunshan Pharmaceutical Launch AI-Powered Chronic Disease Management Initiative  Morningstar

Google News

Nov 19, 2026, 3:15 AM

Piramal Pharma to acquire remaining 26% stake in Yapan Bio - The Hindu

Piramal Pharma to acquire remaining 26% stake in Yapan Bio  The Hindu

Google News

Nov 19, 2026, 3:08 AM

Fangzhou and Baiyunshan Pharmaceutical Launch AI-Powered Chronic Disease Management Initiative - GlobeNewswire

Fangzhou and Baiyunshan Pharmaceutical Launch AI-Powered Chronic Disease Management Initiative  GlobeNewswire

Google News

Nov 19, 2026, 2:10 AM

Faster trials, less red tape. If Europe doesn’t act, patients could miss out on new treatments - EU Perspectives

Faster trials, less red tape. If Europe doesn’t act, patients could miss out on new treatments  EU Perspectives

Google News

Nov 19, 2026, 2:07 AM

Lotte chief calls biotech a key growth engine for group’s future - mkbn.mk.co.kr

Lotte chief calls biotech a key growth engine for group’s future  mkbn.mk.co.kr

Google News

Nov 19, 2026, 1:33 AM

VNVC and the American pharmaceutical company MSD announced a plan to cooperate in vaccine production at the VNVC factory, worth nearly 3 trillion VND. - Vietnam.vn

VNVC and the American pharmaceutical company MSD announced a plan to cooperate in vaccine production at the VNVC factory, worth nearly 3 trillion VND.  Vietnam.vn

Sponsored placement

Featured promotions

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer